LEMNI — 2283558
Application number
2283558
Registration number
TMA1387815
International Registration Number
1752505
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2023-05-02
International Registration
2023-05-02
Registered
2026-02-23
Registration Expiry Date
2033-05-02
Registered Owner
Seqirus Inc.
475 Green Oaks Parkway
Holly Springs NC 27540
UNITED STATES OF AMERICA
Agent
GOWLING WLG (CANADA) LLP
SUITE 2600, 160 ELGIN STREET
OTTAWA
ONTARIO K1P1C3
Documents
Index headings
- LEMNI
Goods (Nice class & Statement)
- 1
- (1) Medical, biological, and pharmaceutical preparations for scientific, research, medical laboratory use, and for the manufacture of pharmaceuticals, namely, bio-chemical preparations containing messenger RNA for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research and medical research, namely, bio-chemical preparations for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory and medical research use in the form of active chemical ingredients for use in the manufacture of drug delivery pharmaceuticals.
- 5
- (2) Vaccines for human use; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, preparations containing messenger RNA for preventing and treating viruses and respiratory disorders; mRNA-based therapeutics and therapeutic agents for in vivo, ex vivo, or in situ prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for pharmaceutical, medical and diagnostic purposes, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals to treat COVID-19, coronavirus disease, and respiratory disorders; drug carriers for medical use, namely, lipid nanoparticles for delivering drugs; lipid nanoparticles for drug delivery sold as an integral component of drugs; pharmaceutical preparations, namely, messenger RNA and delivery agents comprised of lipid nanoparticle tablets and polymers capsules for the delivery of mRNA to human cells; medical, biological, and pharmaceutical preparations for medical laboratory use, namely, preparations containing messenger RNA for preventing and treating viruses and respiratory disorders.
Services (Nice class & Statement)
- 42
- (1) Pharmaceutical research and development; medical research services; biotechnology research, namely, research and development in the medical biotechnology field; scientific research for medical purposes in the fields of COVID-19, coronavirus disease, and respiratory disorders; design and development of medical technology, namely, development of pharmaceutical preparations and medicines; design, engineering, research, and development services in the field of nucleic acid sequencers for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines.
- 44
- (2) Medical services, namely, conducting of medical examinations; providing medical information in the field of medical treatment services; providing medical information in the field of medical treatment services via a website.
Claims
- Priority Filing Date: November 08, 2022, Country or Office: UNITED STATES OF AMERICA, Application No. 97668869 in association with the same kind of goods and in association with the same kind of services
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2023-05-02 | Registration | |
| International Registration | 2023-05-02 | 2033-05-02 | |
| Designation Notification - Madrid Protocol | 2023-09-28 | 2025-03-28 | |
| Created | 2023-09-28 | ||
| Formalized | 2023-09-28 | ||
| Agent Changed | 2023-10-19 | From/De: To/A: 8390 | |
| Notification of Possible Opposition Sent | 2024-07-29 | ||
| Search Recorded | 2024-12-17 | ||
| Examiner's First Report | 2024-12-17 | 2025-06-17 | |
| Total Provisional Refusal | 2024-12-17 | 2025-06-17 | |
| Approved | 2025-09-24 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2025-09-24 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2025-12-03 | Vol.72 Issue 3710 | |
| Opposition Start Date Notice Sent | 2025-12-03 | Requested on 2025/12/03 00:30:04 in program jr500m1 | |
| Registration Pending | 2026-02-23 | ||
| Registered | 2026-02-23 | ||
| Statement of Grant of Protection Sent (following a Provisional Refusal) | 2026-02-23 |